XTX Topco Ltd Has $200,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

XTX Topco Ltd reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 83.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,812 shares of the company's stock after selling 23,444 shares during the quarter. XTX Topco Ltd's holdings in Moderna were worth $200,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. FMR LLC raised its holdings in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after buying an additional 1,282,469 shares during the period. Geode Capital Management LLC increased its holdings in Moderna by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after purchasing an additional 171,774 shares during the last quarter. Invesco Ltd. increased its holdings in Moderna by 24.3% during the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after purchasing an additional 979,858 shares during the last quarter. Norges Bank purchased a new stake in Moderna during the 4th quarter worth approximately $163,833,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Moderna by 9.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company's stock worth $97,472,000 after purchasing an additional 211,426 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MRNA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Friday, March 21st. Leerink Partners lowered their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. UBS Group lowered their price target on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $58.70.

Moderna Price Performance

MRNA traded up $0.36 on Tuesday, reaching $27.82. 5,238,914 shares of the company traded hands, compared to its average volume of 7,367,871. The stock's 50 day moving average price is $30.03 and its 200-day moving average price is $38.15. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47. The company has a market cap of $10.76 billion, a price-to-earnings ratio of -3.00 and a beta of 2.23.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.